Drilldown: Medicines
Appearance
Medicines > onset
:
Over weeks
or
Postprandial glucose effect within days; HbA1c by 12 weeks
or
Urinary concentration adequate within hours 
:
Over weeks
or
Postprandial glucose effect within days; HbA1c by 12 weeks
or
Urinary concentration adequate within hours 
Use the filters below to narrow your results.
Anti-CGRP ligand monoclonal antibody (2) ·
[[:Category:Antibacterials|Antibacterial]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2) ·
[[:Category:Nitrofurans|Nitrofuran]] (1) ·
[[:Category:Urinary_anti-infectives|Urinary anti-infective]] (1)
None (2) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
100 mg PO BID × 5 days (Macrobid) for cystitis; 50-100 mg HS for chronic prophylaxis (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
120 mg/mL prefilled syringe or autoinjector (1) ·
225 mg/1.5 mL prefilled syringe or autoinjector (1) ·
25 mg/5 mL suspension; 25, 50, 100 mg capsules (Macrodantin); 100 mg Macrobid capsule (1) ·
25, 50, 100 mg tablets; combination tablets with metformin (1) ·
5 mg tablets; combination with metformin (1)
'''Avoid at term (38-42 weeks) and during labor''' (risk of neonatal hemolytic anemia, especially with G6PD deficiency); generally safe in earlier pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; avoid (2) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
Showing below up to 5 results in range #1 to #5.

